[go: up one dir, main page]

PE20120026A1 - 2-metil-1-(fenilsulfonil)-4-piperazin-1-il-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 (5-ht6) - Google Patents

2-metil-1-(fenilsulfonil)-4-piperazin-1-il-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 (5-ht6)

Info

Publication number
PE20120026A1
PE20120026A1 PE2011001015A PE2011001015A PE20120026A1 PE 20120026 A1 PE20120026 A1 PE 20120026A1 PE 2011001015 A PE2011001015 A PE 2011001015A PE 2011001015 A PE2011001015 A PE 2011001015A PE 20120026 A1 PE20120026 A1 PE 20120026A1
Authority
PE
Peru
Prior art keywords
alkyl
piperazin
benzimidazole
methyl
hydroxy
Prior art date
Application number
PE2011001015A
Other languages
English (en)
Inventor
Patrick M Andrae
Simon N Haydar
Albert J Robichaud
Heedong Yun
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41404503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PE20120026A1 publication Critical patent/PE20120026A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1a Y R1b SON CADA UNO H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6 SUSTITUIDO CON 0-4 SUSTITUYENTES SELECCIONADOS ENTRE ALQUILO C1-C4, CICLOALQUILO C3-C6; R2 ES H, ALQUILO C1-C4, -CHO, -C(O)(ALQUILO C1-4); R3 ES HIDROXI, HALO, NITRO, CIANO, ENTRE OTROS; R4 ES H, HIDROXI, ALQUILO C1-C6, ENTRE OTROS; R5, R6, R7, R8 Y R9 SON CADA UNO H, HALO, NITRO, CIANO, HIDROXI, ENTRE OTROS; m ES 0-2. SON COMPUESTOS PREFERIDOS: 4-(4-METILPIPERAZIN-1-IL)-1-(NAFTALEN-1-ILSULFONIL)-1H-BENZO[d]IMIDAZOL; 2-METIL-1-(1-NAFTILSULFONIL)-4-PIPERAZIN-1-IL-1H-BENZIMIDAZOL; 1-[(4-CLOROFENIL)SULFONIL]-4-PIPERAZIN-1-IL-1H-BENZIMIDAZOL; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICON FARMACEUTICA Y METODO DE SINTESIS. DICHO COMPUESTO MODULA LA ACTIVIDAD DE 5-HT6, SIENDO UTIL EN EL TRATAMIENTO DE TRANSTORNOS DEL SISTEMA NERVIOSO CENTRAL
PE2011001015A 2008-11-11 2009-11-10 2-metil-1-(fenilsulfonil)-4-piperazin-1-il-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 (5-ht6) PE20120026A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11329608P 2008-11-11 2008-11-11

Publications (1)

Publication Number Publication Date
PE20120026A1 true PE20120026A1 (es) 2012-02-12

Family

ID=41404503

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001015A PE20120026A1 (es) 2008-11-11 2009-11-10 2-metil-1-(fenilsulfonil)-4-piperazin-1-il-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 (5-ht6)

Country Status (41)

Country Link
US (1) US8063053B2 (es)
EP (1) EP2285784B1 (es)
JP (1) JP5087171B2 (es)
KR (1) KR101323417B1 (es)
CN (1) CN102209713B (es)
AP (1) AP2814A (es)
AR (1) AR074325A1 (es)
AU (1) AU2009314221B2 (es)
BR (1) BRPI0920682A2 (es)
CA (1) CA2740262C (es)
CL (1) CL2011001050A1 (es)
CO (1) CO6440548A2 (es)
CR (1) CR20110247A (es)
CU (1) CU24020B1 (es)
CY (1) CY1113025T1 (es)
DK (1) DK2285784T3 (es)
DO (1) DOP2011000130A (es)
EA (1) EA018369B1 (es)
EC (1) ECSP11011045A (es)
ES (1) ES2389694T3 (es)
GE (1) GEP20135805B (es)
HR (1) HRP20120561T1 (es)
IL (1) IL212213A0 (es)
MA (1) MA32788B1 (es)
ME (1) ME01129B (es)
MX (1) MX2011004996A (es)
MY (1) MY156324A (es)
NI (1) NI201100093A (es)
NZ (1) NZ592563A (es)
PE (1) PE20120026A1 (es)
PL (1) PL2285784T3 (es)
PT (1) PT2285784E (es)
RS (1) RS52381B (es)
SA (1) SA109300673B1 (es)
SI (1) SI2285784T1 (es)
SV (1) SV2011003902A (es)
TN (1) TN2011000203A1 (es)
TW (1) TWI481605B (es)
UA (1) UA100192C2 (es)
WO (1) WO2010056644A1 (es)
ZA (1) ZA201103283B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101084212A (zh) * 2004-09-20 2007-12-05 æłœć†œćŒ»èŻć…Źćž æ‚çŽŻèĄç”Ÿç‰©ćŠć…¶äœœäžșçĄŹè„‚é…°CoAćŽ»é„±ć’Œé…¶ä»‹ćŻŒć‰‚çš„ç”šé€”
EP1804799B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580856A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083986A (zh) * 2004-09-20 2007-12-05 æłœć†œćŒ»èŻć…Źćž ćŒçŽŻæ‚çŽŻèĄç”Ÿç‰©ćŠć…¶äœœäžșçĄŹè„‚é…°CoAćŽ»é„±ć’Œé…¶(SCD)æŠ‘ćˆ¶ć‰‚çš„ç”šé€”
CN104557726B (zh) * 2013-10-19 2019-05-24 ćčżäžœäžœé˜łć…‰èŻäžšæœ‰é™ć…Źćž èŠłæ‚çŽŻç±»èĄç”Ÿç‰©ćŠć…¶ćœšèŻç‰©äžŠçš„ćș”甚
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet JagielloƄski Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists
US12398097B2 (en) 2019-07-29 2025-08-26 Vanderbilt University WDR5-MYC inhibitors
CN117242055A (zh) * 2020-04-22 2023-12-15 里科瑞气槆IpæŽ§è‚Ąæœ‰é™èŽŁä»»ć…Źćž é€‰æ‹©æ€§é›Œæż€çŽ ć—äœ“é™è§Łć‰‚çš„ćˆ¶ć€‡

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0773942A1 (en) * 1994-07-26 1997-05-21 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
HUP0003073A3 (en) * 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
GB9716656D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
NZ510180A (en) * 1998-08-10 2002-11-26 Univ California Prodrugs of the pyridyl-methylsulphonyl-benzimidazole type proton pump inhibitors
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0003810D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Novel compounds their use and preparations
IL154685A0 (en) 2000-10-20 2003-09-17 Biovitrum Ab 2-,3-,4-, or 5-substituted-n1-(benzensulfonyl) indoles and their use in therapy
US7034029B2 (en) * 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
AU2005102A (en) * 2000-11-02 2002-05-15 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
EP1401812B1 (en) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
CN1321110C (zh) * 2001-06-15 2007-06-13 ćŒ—Â·ć“ˆć€«æ›Œ-æ‹‰çœ—ćˆ‡æœ‰é™ć…Źćž ć…·æœ‰5ht6ć—äœ“äșČ撌抛的4ïŒć“Œć—ȘćŸșćČć“šèĄç”Ÿç‰©
WO2003026666A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
JP4926943B2 (ja) 2004-04-13 2012-05-09 ă‚·ăƒłă‚ż ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚łăƒŒăƒăƒŹăƒŒă‚·ăƒ§ăƒł ïŒ©ïœŒâˆ’ïŒ‘ïŒ’ç”Łç”Ÿă‚’é˜»ćźłă™ă‚‹äșŒćĄ©
CN101365696A (zh) 2004-07-28 2009-02-11 IrmèŽŁä»»æœ‰é™ć…Źćž 䜜äžșç±»ć›șé†‡æż€çŽ æ žć—äœ“è°ƒèŠ‚ć‰‚çš„ćŒ–ćˆç‰©ć’Œç»„ćˆç‰©
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders

Also Published As

Publication number Publication date
BRPI0920682A2 (pt) 2016-09-27
DOP2011000130A (es) 2017-04-30
HRP20120561T1 (hr) 2012-07-31
TN2011000203A1 (fr) 2012-12-17
EP2285784A1 (en) 2011-02-23
MX2011004996A (es) 2011-05-25
CA2740262C (en) 2013-05-28
MY156324A (en) 2016-02-15
AR074325A1 (es) 2011-01-05
RS52381B (sr) 2012-12-31
KR101323417B1 (ko) 2013-10-29
CN102209713B (zh) 2014-07-02
ECSP11011045A (es) 2011-06-30
ES2389694T3 (es) 2012-10-30
SI2285784T1 (sl) 2012-08-31
NI201100093A (es) 2011-10-31
AP2814A (en) 2013-12-31
JP2012508275A (ja) 2012-04-05
NZ592563A (en) 2012-10-26
KR20110075013A (ko) 2011-07-05
MA32788B1 (fr) 2011-11-01
CY1113025T1 (el) 2016-04-13
AU2009314221B2 (en) 2012-08-30
HK1158647A1 (en) 2012-07-20
ZA201103283B (en) 2012-01-25
WO2010056644A1 (en) 2010-05-20
EP2285784B1 (en) 2012-07-04
SV2011003902A (es) 2011-07-05
TW201022247A (en) 2010-06-16
TWI481605B (zh) 2015-04-21
CN102209713A (zh) 2011-10-05
EA201100696A1 (ru) 2011-10-31
CO6440548A2 (es) 2012-05-15
CL2011001050A1 (es) 2011-08-19
JP5087171B2 (ja) 2012-11-28
AU2009314221A1 (en) 2010-05-20
IL212213A0 (en) 2011-06-30
WO2010056644A8 (en) 2010-11-18
DK2285784T3 (da) 2012-07-23
UA100192C2 (en) 2012-11-26
PT2285784E (pt) 2012-09-19
US8063053B2 (en) 2011-11-22
SA109300673B1 (ar) 2013-05-25
AP2011005664A0 (en) 2011-04-30
ME01129B (me) 2013-03-20
US20100120779A1 (en) 2010-05-13
CA2740262A1 (en) 2010-05-20
PL2285784T3 (pl) 2012-12-31
EA018369B1 (ru) 2013-07-30
CR20110247A (es) 2011-06-24
CU24020B1 (es) 2014-07-30
CU20110101A7 (es) 2012-01-31
GEP20135805B (en) 2013-04-10

Similar Documents

Publication Publication Date Title
PE20120026A1 (es) 2-metil-1-(fenilsulfonil)-4-piperazin-1-il-1h-benzimidazol como ligando de 5-hidroxitriptamina-6 (5-ht6)
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20090772A1 (es) Derivados de bencimidazol
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20140610A1 (es) Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
PE20141726A1 (es) Heterociclilaminas como inhibidores de pi 3k
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
AR076765A1 (es) Compuestos antivirales
PE20091957A1 (es) Compuestos triazina como inhibidores mtor y quinasa pi3
PE20090952A1 (es) Compuestos de pirazol moduladores de raf
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
PE20141000A1 (es) Ureas asimetricas y usos medicos de las mismas
ES2669189T3 (es) Compuestos de carbazol Ăștiles como inhibidores del bromodominio
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed